Hanbang Cardio-Renal Research Center, Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan 54538, Korea.
College of Oriental Medicine, Professional Graduate School of Oriental Medicine, Wonkwang University, Iksan 54538, Korea.
Nutrients. 2021 Nov 22;13(11):4177. doi: 10.3390/nu13114177.
Diabetic cardiovascular dysfunction is a representative complication of diabetes. Inflammation associated with the onset and exacerbation of type 2 diabetes mellitus (T2DM) is an essential factor in the pathogenesis of diabetic cardiovascular complications. Diabetes-induced myocardial dysfunction is characterized by myocardial fibrosis, which includes structural heart changes, myocardial cell death, and extracellular matrix protein accumulation. The mice groups in this study were divided as follows: Cont, control (db/m mice); T2DM, type 2 diabetes mellitus mice (db/db mice); Vil.G, db/db + vildagliptin 50 mg/kg/day, positive control, dipeptidyl peptidase-4 (DPP-4) inhibitor; Bla.C, db/db + blackcurrant 200 mg/kg/day. In this study, Bla.C treatment significantly improved the homeostatic model evaluation of glucose, insulin, and insulin resistance (HOMA-IR) indices and diabetic blood markers such as HbA1c in T2DM mice. In addition, Bla.C improved cardiac function markers and cardiac thickening through echocardiography. Bla.C reduced the expression of fibrosis biomarkers, elastin and type IV collagen, in the left ventricle of a diabetic cardiopathy model. Bla.C also inhibited TD2M-induced elevated levels of inflammatory cytokines in cardiac tissue (IL-6, IL-1β, TNF-α, and TGF-β). Thus, Bla.C significantly improved cardiac inflammation and cardiovascular fibrosis and dysfunction by blocking inflammatory cytokine activation signals. This showed that Bla.C treatment could ameliorate diabetes-induced cardiovascular complications in T2DM mice. These results provide evidence that Bla.C extract has a significant effect on the prevention of cardiovascular fibrosis, inflammation, and consequent diabetes-induced cardiovascular complications, directly or indirectly, by improving blood glucose profile.
糖尿病心血管功能障碍是糖尿病的代表性并发症。与 2 型糖尿病(T2DM)的发病和恶化相关的炎症是糖尿病心血管并发症发病机制中的一个重要因素。糖尿病引起的心肌功能障碍的特征是心肌纤维化,包括结构心脏变化、心肌细胞死亡和细胞外基质蛋白积累。本研究中的小鼠分组如下:Cont,对照组(db/m 小鼠);T2DM,2 型糖尿病小鼠(db/db 小鼠);Vil.G,db/db+维格列汀 50mg/kg/天,阳性对照,二肽基肽酶-4(DPP-4)抑制剂;Bla.C,db/db+黑加仑 200mg/kg/天。在这项研究中,Bla.C 治疗显著改善了 T2DM 小鼠的葡萄糖、胰岛素和胰岛素抵抗(HOMA-IR)指数以及糖尿病血液标志物,如 HbA1c 的稳态模型评估。此外,Bla.C 通过超声心动图改善了心脏功能标志物和心脏增厚。Bla.C 降低了糖尿病心肌病模型左心室中纤维化生物标志物弹性蛋白和 IV 型胶原的表达。Bla.C 还抑制了 TD2M 诱导的心脏组织中炎症细胞因子(IL-6、IL-1β、TNF-α 和 TGF-β)水平的升高。因此,Bla.C 通过阻断炎症细胞因子激活信号,显著改善了心脏炎症和心血管纤维化及功能障碍。这表明 Bla.C 治疗可改善 T2DM 小鼠的糖尿病引起的心血管并发症。这些结果提供了证据,表明 Bla.C 提取物通过改善血糖谱,直接或间接地对预防心血管纤维化、炎症和随后的糖尿病引起的心血管并发症具有显著作用。